ArticleIndian journal of ophthalmology2026
Clinical characteristics and treatment of Morbihan disease of the eyelids: A single-center retrospective study.
Article in Indian journal of ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate clinical and histopathological characteristics and treatment outcomes of Morbihan disease (MD) of eyelids, a rare condition characterized by chronic erythematous edema.
designRetrospective study.
methodsClinical records of patients diagnosed with eyelid and facial MD were reviewed to assess clinical features, treatment outcomes, recurrence, and histopathological findings. Nonsurgical treatments were categorized as observation, oral steroids (oral group), intralesional steroid injections (injection group), and combination group. Treatment response was classified as complete (CR), partial (PR), or no response. Intralesional injections were subdivided into low-dose (<20 mg) and high-dose (≥20 mg). Recurrence was defined as erythematous edema reappearing after CR.
resultsThe study included 67 patients (mean age, 54.3 ± 11.9 years; 65.7% male) with a mean follow-up of 1.69 ± 1.83 years. Of 57 patients who underwent nonsurgical treatments, significant differences in treatment response were observed among oral (n = 13), injection (n = 16), and combination (n = 28) groups ( P < 0.001). Injection (56.2%) and combination (64.2%) groups showed higher response rates (CR or PR) than the oral group (38.4%) ( P < 0.05). Recurrence was higher in the oral group (53.3%) than in the injection (26.7%) and combination (20.0%) groups ( P = 0.018 ) . High-dose injection showed better response than low-dose (70.8% vs. 50.0%, P = 0.017). Debulking surgery with blepharoplasty was performed in 23 patients (40.4%), with 91.3% achieving long-term control. Common histopathological findings included dermal edema (91.3%) and dilated lymphatic or blood vessels (60.8%).
conclusionsIntralesional steroid injections, particularly at doses ≥20 mg, were more effective than oral steroids in treating eyelid MD. Eyelid debulking surgery is beneficial in refractory or recurrent cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.